Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
about
Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CRecent Advances in Application of Pharmacogenomics for BiotherapeuticsPharmacogenomics of antimicrobial agents.Translational Genomics in Low- and Middle-Income Countries: Opportunities and Challenges.Secondary Structural Elements of the HCV X-region Involved in Viral ReplicationInterferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.Recent advances in management of the HIV/HCV coinfected patient.PharmGKB summary: peginterferon-α pathway.Hepatitis C-associated liver carcinogenesis: role of PML nuclear bodies.The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4.An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms.Pharmacogenetics of ribavirin-induced anemia in HCV patients.The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients.Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.
P2860
Q28080225-1E34FE74-25AA-41DD-BDA6-B7F0429D35B9Q29247996-EB106491-FEA8-4669-B4F1-C02FA2AC63C9Q34977413-40DAC861-0803-4280-BD36-A9EC35823204Q35888017-61744904-D718-4541-9D2B-A1B752D1312BQ35972684-254B07A9-528F-4998-B733-277A08E3AC7CQ36134478-8713C89E-F2A1-4185-81C3-F06357342EE6Q36575497-B70ADBB7-99C5-4C7E-970B-898A4D3C1F76Q36590755-D0D57952-7FDD-40D8-BCCC-CCFA393F297EQ38254120-D4D1E5E9-217E-49F6-8254-E21552C487E6Q39117290-761B5BF9-30D1-4A20-B4DC-F81505C0E50EQ40055793-8E02CA36-B0EA-478F-AB24-4D9243B412AFQ40650428-9798D47E-0C85-4F3D-B4D1-725000A3D9D3Q48098965-C73BDCCD-C19B-498A-8879-AE73E65F0E55Q53684076-E08BB8FD-01E2-488C-A277-FD12BA13308F
P2860
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacogenetics of hepatitis ...... direct-acting antiviral agents
@ast
Pharmacogenetics of hepatitis ...... direct-acting antiviral agents
@en
type
label
Pharmacogenetics of hepatitis ...... direct-acting antiviral agents
@ast
Pharmacogenetics of hepatitis ...... direct-acting antiviral agents
@en
prefLabel
Pharmacogenetics of hepatitis ...... direct-acting antiviral agents
@ast
Pharmacogenetics of hepatitis ...... direct-acting antiviral agents
@en
P2860
P356
P1476
Pharmacogenetics of hepatitis ...... direct-acting antiviral agents
@en
P2860
P356
10.2147/HMER.S41127
P577
2014-06-24T00:00:00Z